| Date Filed | Type | Description |
| 08/08/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/08/2023 |
8-K
| Quarterly results |
| 06/02/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"FIRST: The name of the Corporation is Acorda Therapeutics, Inc. SECOND: The registered office of the Corporation is to be located at 1209 Orange Street, Wilmington, , Delaware 19801. The name of its registered agent at that address is The Corporation Trust Company. THIRD: The purpose of the Corporation is to engage in any lawful act or activity for which a corporation may be organized under the General Corporation Law of Delaware. FOURTH: The Corporation shall have the authority to issue a total of 23,083,333 shares, divided into classes of 3,083,333 shares of Common Stock, $0.001 par value per share , and 20,000,000 shares of Preferred Stock, $0.001 par value per share . Pursuant to the DGCL, at 4:01 p.m. Eastern Time on the date of filing of this Amended and Restated Certificate of Incor...",
"Acorda Therapeutics Announces Completion of 1-for-20 Reverse Stock Split" |
|
| 06/01/2023 |
8-K
| Other Events Interactive Data |
| 05/31/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/11/2023 |
8-K
| Quarterly results |
| 05/10/2023 |
SC 13D/A
| DAVIDSON KEMPNER CAPITAL MANAGEMENT LP reports a 4.5% stake in Acorda Therapeutics, Inc. |
| 05/10/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 05/08/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 04/27/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/27/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/04/2023 |
4
| COHEN RON (President and CEO) has filed a Form 4 on Acorda Therapeutics, Inc.|
Txns:
| Granted 168,800 options to buy
@ $0.586, valued at
$98.9k
|
|
| 04/04/2023 |
4
| Clem Kerry M (Chief Commercial Officer) has filed a Form 4 on Acorda Therapeutics, Inc.|
Txns:
| Granted 77,300 options to buy
@ $0.586, valued at
$45.3k
|
|
| 04/04/2023 |
4
| Belloff Neil S. (General Counsel and Corp Secy) has filed a Form 4 on Acorda Therapeutics, Inc.|
Txns:
| Granted 77,300 options to buy
@ $0.586, valued at
$45.3k
|
|
| 03/20/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/10/2023 |
SC 13D/A
| DAVIDSON KEMPNER CAPITAL MANAGEMENT LP reports a 7.4% stake in Acorda Therapeutics, Inc. |
| 02/14/2023 |
SC 13G/A
| CANYON CAPITAL ADVISORS LLC reports a 0% stake in Acorda Therapeutics Inc |
| 02/13/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 01/23/2023 |
SC 13D/A
| DAVIDSON KEMPNER CAPITAL MANAGEMENT LP reports a 8.6% stake in Acorda Therapeutics, Inc. |
| 01/05/2023 |
8-K
| Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits... |
| 01/04/2023 |
4
| Varian John (Director) has filed a Form 4 on ACORDA THERAPEUTICS INC|
Txns:
| Granted 4,712 options to buy
@ $0.7667, valued at
$3.6k
|
|
| 12/23/2022 |
8-K
| Regulation FD Disclosure Interactive Data |
| 12/22/2022 |
8-K
| Quarterly results |
| 12/21/2022 |
8-K
| Quarterly results |
| 12/05/2022 |
8-K
| Quarterly results |
| 11/14/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/14/2022 |
8-K
| Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits Interac... |
| 11/07/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 11/04/2022 |
8-K
| Quarterly results |
| 11/01/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 11/01/2022 |
8-K
| Quarterly results |
| 10/31/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 10/31/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
|